Immunohistochemical Study of Estrogen and Progesterone Receptor Expression in Endometrial Carcinoma

Dr. Manju Singh Sirohi; Dr. Ankita Srivastava; Dr. Ashwani Tripathi; Dr. Tripti Singh; Dr. Chanchal Rana; Dr. Ajay Singh; Dr. U.S. Singh; Dr. Nikhilesh Kumar; Dr. Monika Gupta; Dr. Ved Prakash

doi:10.36948/ijfmr.2024.v06i01.12999

Immunohistochemical Study of Estrogen and Progesterone Receptor Expression in Endometrial Carcinoma

Author(s)	Dr. Manju Singh Sirohi, Dr. Ankita Srivastava, Dr. Ashwani Tripathi, Dr. Tripti Singh, Dr. Chanchal Rana, Dr. Ajay Singh, Dr. U.S. Singh, Dr. Nikhilesh Kumar, Dr. Monika Gupta, Dr. Ved Prakash
Country	India
Abstract	BACKGROUND: Endometrial cancer is the fourth most common cancer affecting the women both from the point of view of incidence as well as mortality. ER/PR positivity helps to determine the need for hormonal treatment for endometrial cancer. METERIAL AND METHOD It is a reterospective study on 22 histopathologically proven cases of endometrial carcinoma between the age group 30 to 80 yr from 1 Jan 2021 to 30 June 2022. Those cases with inadequate sample or with history of pregnancy were excluded from study. ER and PR expression was seen with Immunohistochemistry kit protocol. RESULTS: Mean age of patients was 57.77 yrs. Endometrial carcinoma is more common in postmenopausal females. Bleeding per vaginum is the chief complaint. Most of the cases were well differentiated and of low grade.ER expression is positive in (15/17 88.2% )of cases of low grade /well differentiated , (4/4,100%) in moderately differentiated and not seen in high grade/ poorly differentiated endometrial carcinoma .PR expression seen in low grade/well differentiated is (14/17,82.4%) , in moderately differentiated is( 4/4,100%) and in high grade /poorly differentiated is (1/1, 100%)and not seen in high grade or poorly differentiated endometrial carcinoma .As the tumor invades deep in the myometrium ER and PR expression decreases. CONCLUSION: ER and PR are important prognostic biomarkers to predict response to anti hormonal therapy.
Keywords	Estrogen receptor, Progesterone receptor.
Field	Medical / Pharmacy
Published In	Volume 6, Issue 1, January-February 2024
Published On	2024-02-20
Cite This	Immunohistochemical Study of Estrogen and Progesterone Receptor Expression in Endometrial Carcinoma - Dr. Manju Singh Sirohi, Dr. Ankita Srivastava, Dr. Ashwani Tripathi, Dr. Tripti Singh, Dr. Chanchal Rana, Dr. Ajay Singh, Dr. U.S. Singh, Dr. Nikhilesh Kumar, Dr. Monika Gupta, Dr. Ved Prakash - IJFMR Volume 6, Issue 1, January-February 2024. DOI 10.36948/ijfmr.2024.v06i01.12999
DOI	https://doi.org/10.36948/ijfmr.2024.v06i01.12999
Short DOI	https://doi.org/gtjt3d

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 4 Cover Page Vol 6 Isu 3 Cover Page Vol 6 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Immunohistochemical Study of Estrogen and Progesterone Receptor Expression in Endometrial Carcinoma

Share this